Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP

Autor: Guangming Han, Pedro Farinha, Joseph M. Connors, Nathalie A. Johnson, Christian Steidl, Jesse Shustik, Susana Ben Neriah, Randy D. Gascoyne, Laurie H. Sehn, Douglas E. Horsman
Rok vydání: 2009
Předmět:
Adult
Male
Oncology
medicine.medical_specialty
Adolescent
CHOP
Immunophenotyping
Cohort Studies
Antibodies
Monoclonal
Murine-Derived
Young Adult
International Prognostic Index
immune system diseases
hemic and lymphatic diseases
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Tumor
medicine
Humans
Gene Rearrangement
B-Lymphocyte
Cyclophosphamide
Aged
Retrospective Studies
Aged
80 and over
BCL6 Gene Rearrangement
business.industry
Hematology
Gene rearrangement
Middle Aged
medicine.disease
BCL6
Lymphoma
DNA-Binding Proteins
Survival Rate
Treatment Outcome
Doxorubicin
Vincristine
Proto-Oncogene Proteins c-bcl-6
Cancer research
Prednisone
Female
Original Article
Rituximab
Lymphoma
Large B-Cell
Diffuse
business
Diffuse large B-cell lymphoma
Follow-Up Studies
medicine.drug
Zdroj: PubMed Central
ISSN: 1592-8721
0390-6078
Popis: Background BCL6 gene rearrangement is the most frequent chromosomal abnormality in diffuse large B-cell lymphoma, a malignancy characterized by genetic heterogeneity and wide variability in clinical outcome. The prognostic significance of BCL6 rearrangement has not been evaluated in the context of rituximab therapy for diffuse large B-cell lymphoma. We analyzed the effect of the BCL6 rearrangement on survival in patients with diffuse large B-cell lymphoma treated with CHOP and CHOP plus rituximab (R-CHOP). Design and Methods BCL6 rearrangement status was analyzed by fluorescence in situ hybridization with break-apart probes in 164 patients with diffuse large B-cell lymphoma treated with CHOP (n=65) or R-CHOP (n=99). Cell-of-origin immunophenotype including BCL6 protein expression were determined by immunohistochemistry on a tissue microarray. Results BCL6 rearrangement was detected in 19.5% of cases. The presence of the gene rearrangement was associated with a non-germinal center B-cell immunophenotype ( P =0.006), and showed no correlation with BCL6 protein expression. A trend toward inferior overall survival was observed in association with the BCL6 rearrangement among patients treated with R-CHOP ( P =0.08), but not among patients treated with CHOP ( P =0.64). However, BCL6 rearrangement also correlated with a high International Prognostic Index score ( P =0.02), and did not demonstrate independent prognostic value by multivariate analysis. Conclusions The introduction of rituximab may have altered the prognostic impact of BCL6 gene rearrangement in patients with diffuse large B-cell lymphoma. However, prospective analysis within large randomized clinical trials will be needed to clarify the prognostic significance of this biomarker in the rituximab era.
Databáze: OpenAIRE
Externí odkaz: